LEKSUM and SLU Partner to Pioneer Muscle Research in Unique ICU Lab
TL;DR
Leksum LLC's partnership with SLU establishes a unique muscle research lab, offering unparalleled insights into ICU-related muscle myopathies, positioning Leksum as a leader in advanced biologic therapies.
The lab utilizes a unique experimental ICU model to study long-term muscle mass and function loss, enabling detailed mechanistic and intervention studies under ICU conditions.
This collaboration aims to develop therapies for muscle myopathies, improving the quality of life for millions of ICU patients worldwide by addressing critical illness myopathy.
Leksum and SLU's groundbreaking lab can replicate long-term ICU conditions, a world-first, paving the way for innovative treatments in muscle myopathy research.
Found this article helpful?
Share it with your network and spread the knowledge!
LEKSUM LLC has entered into a significant partnership with the Swedish University of Agricultural Sciences (SLU) to host an innovative muscle research laboratory in Uppsala, Sweden. This facility, under the guidance of Dr. Lars Larsson, LEKSUM's Chief Scientific Officer, is set to revolutionize the study of muscle myopathies, particularly those arising from long-term mechanical ventilation in intensive care units (ICUs). The lab's unique experimental ICU model overcomes the limitation of early mortality seen in other studies, enabling long-term mechanistic and intervention research.
The collaboration marks a pivotal step in understanding and treating critical illness myopathy (CIM), a condition that develops after prolonged ICU stays involving mechanical ventilation and immobilization. With the capability to replicate long-term survival, the lab provides an unparalleled opportunity to study the mechanisms behind muscle mass and function loss, including myosin modifications and preferential myosin loss. This research is crucial for developing both prophylactic and therapeutic approaches to combat muscle myopathies, which impact millions of patients annually.
Dr. Larsson emphasized the importance of this partnership, highlighting its potential to advance the development of biologic therapies for acquired muscle myopathies. The LEKSUM-SLU lab stands as the only facility worldwide capable of conducting such extensive studies under ICU conditions, offering hope for improved treatments and outcomes for patients globally.
Curated from Reportable
